Viking Therapeutics, Inc
VKTXViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for metabolic and endocrine disorders. The company utilizes its proprietary platform to advance novel treatments targeting liver and metabolic diseases, as well as rare genetic disorders.
Company News
The article explores two promising healthcare stocks - Viking Therapeutics and CRISPR Therapeutics - as potential investment opportunities in the weight loss drug and gene editing markets, highlighting their upcoming clinical milestones and growth potential.
Viking Therapeutics announced participation in two healthcare investor conferences in November 2025, including a fireside chat at Stifel and a corporate presentation at Jefferies, highlighting their ongoing clinical-stage research in metabolic and endocrine disorder therapies.
Viking Therapeutics, a clinical-stage biopharmaceutical company, is showing promise with its injectable weight loss treatment VK2735 in Phase 3 trials. Despite being pre-revenue, the stock has risen over 36% in three months, with analysts projecting significant potential in the growing GLP-1 market.
Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesi...
Eli Lilly and Novo Nordisk have created the biggest ever pharmaceutical market with its miraculous weight loss drugs. Read more on LLY stock here.
